Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Varsha Gandhi, PhD, on Ibrutinib

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Apr
08
Today In Oncology
Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis
Long-Term Outcomes With Pralsetinib in RET Fusion–Positive NSCLC
IMPT vs IMRT in Oropharyngeal Cancer
Metastatic Papillary Renal Cancer Final Results With Savolitinib and Durvalumab
Damaging Missense Variants in Innate Immunity Genes Linked to Earlier Breast Cancer Onset in BRCA1 Carriers
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo